Grace Therapeutics, Inc. (GRCE) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025. Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.) is a clinical-stage biopharmaceutical company focused on developing novel drug delivery technologies for rare and orphan diseases. The company recently completed a domestication from Canada to Delaware and changed its name in October 2024. Its primary focus is the lead drug candidate GTx-104, an injectable formulation of nimodipine for aneurysmal subarachnoid hemorrhage (aSAH), for which a New Drug Application (NDA) was submitted to the FDA on June 25, 2025.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,362) | $(2,617) |
| Loss Per Share (Basic & Diluted) | $(0.21) | $(0.24) |
| Operating Expenses | $(3,090) | $(4,963) |
| Research & Development (R&D) | $(955) | $(2,708) |
| General & Administrative (G&A) | $(2,135) | $(2,255) |
| Cash and Cash Equivalents (End of Period) | $20,005 | $19,394 |
| Net Cash Used in Operating Activities | $(1,801) | $(3,596) |
| Total Assets | $69,805 | $71,993 |
| Total Liabilities | $6,255 | $5,383 |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by $745 thousand compared to Q1 2024. This was primarily driven by a $1,882 thousand unfavorable change in the fair value of derivative warrant liabilities and the absence of a $724 thousand income tax benefit recorded in the prior year.
- Expense Reduction: Operating expenses decreased significantly by $1,873 thousand. R&D expenses dropped $1,753 thousand due to the completion of the pivotal Phase 3 STRIVE-ON trial for GTx-104. G&A expenses decreased $120 thousand, largely due to reduced professional fees related to the company's domestication.
- Liquidity: Cash balances decreased by $2,128 thousand during the quarter, primarily due to operating cash outflows and stock issuance costs. However, the company maintains a cash runway of at least 12 months following a $13.7 million private placement in February 2025.
- Derivative Warrant Liability: The liability increased from $1,141 thousand to $1,628 thousand due to fluctuations in the company's stock price.
Guidance, Outlook, and Risks
- Regulatory Milestone: The company submitted an NDA for GTx-104 on June 25, 2025. Management expects to prioritize commercial planning and team buildout pending FDA acceptance and approval.
- Pipeline Strategy: Development of secondary candidates GTx-102 (Ataxia Telangiectasia) and GTx-101 (Postherpetic Neuralgia) is deprioritized and contingent on securing additional funding or strategic partnerships.
- Capital Needs: The company expects to incur continued operating losses and will require additional financing to fund daily operations beyond the next 12 months. Future funding may come from equity, debt, or non-dilutive sources such as collaborations.
- Risks: Key risks include the uncertainty of FDA approval for GTx-104, the inability to raise additional capital on acceptable terms, and the volatility of derivative warrant liabilities impacting net loss.
Investor Verification Checklist
- NDA Acceptance: Verify the FDA's acceptance of the GTx-104 NDA filed on June 25, 2025, and the projected timeline for a decision.
- Cash Runway: Confirm the current cash burn rate and the sufficiency of the $20.0 million cash balance to fund operations through the FDA review period.
- Warrant Liability Volatility: Monitor the fair value of derivative warrant liabilities, as changes in stock price directly impact reported net loss without affecting cash flow.
- Commercialization Plan: Review details on the planned commercial infrastructure and sales force buildout for GTx-104 upon potential approval.
- Secondary Pipeline: Assess any updates regarding potential licensing or sale of GTx-102 and GTx-101 to offset development costs.